|
FY2013
12 months to Dec 31, 2013
|
|
|---|---|
| Revenues: | |
| Collaboration agreements | |
| Operating expenses: | |
| Research and development | |
| General and administrative | |
| Gain on sale of kinase profiling services business | |
| Total operating expenses | |
| Loss from operations | |
| Other income (expense): | |
| Interest expense | |
| Other income (expense) | |
| Change in fair value of warrant and derivative liabilities | |
| Total other income (expense) | |
| Loss before income taxes | |
| Benefit for income taxes | |
| Consolidated net loss | |
| Net loss/(income) attributable to redeemable non-controlling interest | |
| Net loss attributable to Ambit Biosciences Corporation | |
| Other comprehensive income/(loss): | |
| Foreign currency translation | |
| Comprehensive loss | |
| Net loss per share attributable to common stockholders, basic and diluted | |
| Weighted average shares outstanding, basic and diluted |
Loading...
